blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2240028

EP2240028 - Pyrazolopyrimidine-4,6-dione derivatives and their use as pharmaceutical [Right-click to bookmark this link]
Former [2010/42]ORGANIC COMPOUNDS
[2016/08]
StatusNo opposition filed within time limit
Status updated on  26.05.2017
Database last updated on 03.10.2024
Most recent event   Tooltip21.09.2018Lapse of the patent in a contracting state
New state(s): MT		published on 24.10.2018  [2018/43]
Applicant(s)For all designated states
Intra-Cellular Therapies, Inc.
430 East 29th Street, Suite 900
New York, NY 10016 / US
[2016/33]
Former [2010/42]For all designated states
Intra-Cellular Therapies, Inc.
3960 Broadway
New York, NY 10032 / US
Inventor(s)01 / LI, Peng
3960 Broadway
New York NY 10032 / US
02 / ZHAO, Jun
3960 Broadway
New York NY 10032 / US
03 / ZHENG, Hailin
3960 Broadway
New York NY 10032 / US
 [2010/42]
Representative(s)McNab, Donald C., et al
Marks & Clerk LLP
Atholl Exchange
6 Canning Street
Edinburgh EH3 8EG / GB
[2013/42]
Former [2010/42]McNab, Donald C.
Marks & Clerk LLP Aurora 120 Bothwell Street Glasgow
G2 7JS / GB
Application number, filing date08856780.506.12.2008
[2010/42]
WO2008US13410
Priority number, dateUS2007001204506.12.2007         Original published format: US 12045
[2010/42]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2009073210
Date:11.06.2009
Language:EN
[2009/24]
Type: A1 Application with search report 
No.:EP2240028
Date:20.10.2010
Language:EN
The application published by WIPO in one of the EPO official languages on 11.06.2009 takes the place of the publication of the European patent application.
[2010/42]
Type: B1 Patent specification 
No.:EP2240028
Date:20.07.2016
Language:EN
[2016/29]
Search report(s)International search report - published on:US11.06.2009
(Supplementary) European search report - dispatched on:EP12.01.2012
ClassificationIPC:A01N43/56, C07D487/04, A61K31/519, A61P25/16, A61P25/18, A61P25/22, A61P25/24, A61P25/28, A61P35/00, A61P37/00, A61P9/04, A61P15/00
[2012/06]
CPC:
C07D487/04 (EP,US); C07D403/10 (KR); A61K31/519 (EP,US);
A61K45/06 (US); A61P11/00 (EP); A61P11/02 (EP);
A61P11/06 (EP); A61P13/08 (EP); A61P15/00 (EP);
A61P15/08 (EP); A61P15/10 (EP); A61P19/10 (EP);
A61P25/00 (EP); A61P25/14 (EP); A61P25/16 (EP);
A61P25/18 (EP); A61P25/20 (EP); A61P25/22 (EP);
A61P25/24 (EP); A61P25/28 (EP); A61P25/30 (EP);
A61P29/00 (EP); A61P35/00 (EP); A61P37/00 (EP);
A61P37/06 (EP); A61P43/00 (EP); A61P5/00 (EP);
A61P5/24 (EP); A61P9/00 (EP); A61P9/04 (EP);
A61P9/12 (EP) (-)
Former IPC [2010/42]A01N43/56
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2016/29]
Former [2010/42]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:Pyrazolopyrimidine-4,6-dione derivate und deren Anwendung als Pharmaceutika[2016/08]
English:Pyrazolopyrimidine-4,6-dione derivatives and their use as pharmaceutical[2016/08]
French:Dérivés de Pyrazolopyrimidine-4,6-dione et leur utilisation pharmaceutique[2016/08]
Former [2010/42]ORGANISCHE VERBINDUNGEN
Former [2010/42]ORGANIC COMPOUNDS
Former [2010/42]COMPOSÉS ORGANIQUES
Entry into regional phase06.07.2010National basic fee paid 
06.07.2010Search fee paid 
06.07.2010Designation fee(s) paid 
06.07.2010Examination fee paid 
Examination procedure06.07.2010Examination requested  [2010/42]
10.08.2012Amendment by applicant (claims and/or description)
21.09.2012Despatch of a communication from the examining division (Time limit: M04)
01.02.2013Reply to a communication from the examining division
08.09.2015Despatch of a communication from the examining division (Time limit: M04)
18.01.2016Reply to a communication from the examining division
05.02.2016Communication of intention to grant the patent
10.06.2016Fee for grant paid
10.06.2016Fee for publishing/printing paid
10.06.2016Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  21.09.2012
Opposition(s)21.04.2017No opposition filed within time limit [2017/26]
Fees paidRenewal fee
15.12.2010Renewal fee patent year 03
12.12.2011Renewal fee patent year 04
11.12.2012Renewal fee patent year 05
12.12.2013Renewal fee patent year 06
11.12.2014Renewal fee patent year 07
10.12.2015Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU06.12.2008
AT20.07.2016
BE20.07.2016
CY20.07.2016
CZ20.07.2016
DK20.07.2016
EE20.07.2016
FI20.07.2016
HR20.07.2016
LT20.07.2016
LV20.07.2016
MC20.07.2016
NL20.07.2016
PL20.07.2016
RO20.07.2016
SE20.07.2016
SI20.07.2016
SK20.07.2016
TR20.07.2016
BG20.10.2016
NO20.10.2016
GR21.10.2016
IS20.11.2016
PT21.11.2016
IE06.12.2016
LU06.12.2016
MT06.12.2016
[2018/43]
Former [2018/29]HU06.12.2008
AT20.07.2016
BE20.07.2016
CY20.07.2016
CZ20.07.2016
DK20.07.2016
EE20.07.2016
FI20.07.2016
HR20.07.2016
LT20.07.2016
LV20.07.2016
MC20.07.2016
NL20.07.2016
PL20.07.2016
RO20.07.2016
SE20.07.2016
SI20.07.2016
SK20.07.2016
TR20.07.2016
BG20.10.2016
NO20.10.2016
GR21.10.2016
IS20.11.2016
PT21.11.2016
IE06.12.2016
LU06.12.2016
Former [2018/28]HU06.12.2008
AT20.07.2016
BE20.07.2016
CY20.07.2016
CZ20.07.2016
DK20.07.2016
EE20.07.2016
FI20.07.2016
HR20.07.2016
LT20.07.2016
LV20.07.2016
MC20.07.2016
NL20.07.2016
PL20.07.2016
RO20.07.2016
SE20.07.2016
SI20.07.2016
SK20.07.2016
BG20.10.2016
NO20.10.2016
GR21.10.2016
IS20.11.2016
PT21.11.2016
IE06.12.2016
LU06.12.2016
Former [2017/49]AT20.07.2016
BE20.07.2016
CZ20.07.2016
DK20.07.2016
EE20.07.2016
FI20.07.2016
HR20.07.2016
LT20.07.2016
LV20.07.2016
MC20.07.2016
NL20.07.2016
PL20.07.2016
RO20.07.2016
SE20.07.2016
SI20.07.2016
SK20.07.2016
BG20.10.2016
NO20.10.2016
GR21.10.2016
IS20.11.2016
PT21.11.2016
IE06.12.2016
LU06.12.2016
Former [2017/45]AT20.07.2016
BE20.07.2016
CZ20.07.2016
DK20.07.2016
EE20.07.2016
FI20.07.2016
HR20.07.2016
LT20.07.2016
LV20.07.2016
MC20.07.2016
NL20.07.2016
PL20.07.2016
RO20.07.2016
SE20.07.2016
SI20.07.2016
SK20.07.2016
BG20.10.2016
NO20.10.2016
GR21.10.2016
IS20.11.2016
PT21.11.2016
Former [2017/37]AT20.07.2016
BE20.07.2016
CZ20.07.2016
DK20.07.2016
EE20.07.2016
FI20.07.2016
HR20.07.2016
LT20.07.2016
LV20.07.2016
NL20.07.2016
PL20.07.2016
RO20.07.2016
SE20.07.2016
SI20.07.2016
SK20.07.2016
BG20.10.2016
NO20.10.2016
GR21.10.2016
IS20.11.2016
PT21.11.2016
Former [2017/31]AT20.07.2016
BE20.07.2016
CZ20.07.2016
DK20.07.2016
EE20.07.2016
FI20.07.2016
HR20.07.2016
LT20.07.2016
LV20.07.2016
NL20.07.2016
PL20.07.2016
RO20.07.2016
SE20.07.2016
SK20.07.2016
BG20.10.2016
NO20.10.2016
GR21.10.2016
IS20.11.2016
PT21.11.2016
Former [2017/13]AT20.07.2016
BE20.07.2016
FI20.07.2016
HR20.07.2016
LT20.07.2016
LV20.07.2016
NL20.07.2016
PL20.07.2016
SE20.07.2016
NO20.10.2016
GR21.10.2016
IS20.11.2016
PT21.11.2016
Former [2017/11]AT20.07.2016
BE20.07.2016
FI20.07.2016
HR20.07.2016
LT20.07.2016
NL20.07.2016
PL20.07.2016
SE20.07.2016
NO20.10.2016
GR21.10.2016
IS20.11.2016
PT21.11.2016
Former [2017/10]BE20.07.2016
FI20.07.2016
HR20.07.2016
LT20.07.2016
NL20.07.2016
PL20.07.2016
SE20.07.2016
NO20.10.2016
IS20.11.2016
Former [2017/09]FI20.07.2016
LT20.07.2016
NL20.07.2016
NO20.10.2016
Former [2017/07]LT20.07.2016
Documents cited:Search[A]EP0166054  (TAKEDA CHEMICAL INDUSTRIES LTD [JP]) [A] 1-18 * abstract *;
 [A]EP0237289  (TAKEDA CHEMICAL INDUSTRIES LTD [JP]) [A] 1-18 * abstract *;
 [A]WO9846606  (ASTRA PHARMA PROD [GB], et al) [A] 1-18 * claim - *;
 [A]US6133273  (GILBERT ADAM MATTHEW [US], et al) [A] 1-18 * example D *;
 [A]WO03002567  (ASTRAZENECA AB [SE], et al) [A] 1-18* abstract *;
 [AP]WO2007143705  (INTRA CELLULAR THERAPIES INC [US], et al) [AP] 1-18 * the whole document *
International search[Y]WO9846606  (ASTRA PHARMA PROD [GB], et al);
 [Y]US6133273  (GILBERT ADAM MATTHEW [US], et al);
 [Y]WO2006133261  (INTRA CELLULAR THERAPIES INC [US], et al)
by applicant   - MANI ET AL., SCIENCE, (2000), vol. 287, page 1053
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.